{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:39:46Z","timestamp":1761514786855,"version":"build-2065373602"},"reference-count":135,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Minister of Science and Higher Education","award":["002\/ RID\/2018\/19."],"award-info":[{"award-number":["002\/ RID\/2018\/19."]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>COVID-19 infection poses an important clinical therapeutic problem, especially in patients with coexistent diseases such as type 2 diabetes. Potential pathogenetic links between COVID-19 and diabetes include inflammation, effects on glucose homeostasis, haemoglobin deoxygenation, altered immune status and activation of the renin-angiotensin-aldosterone system (RAAS). Moreover, drugs often used in the clinical care of diabetes (dipeptidyl peptidase 4 inhibitors, glucagon-like peptide 1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, metformin and insulin) may influence the course of SARS-CoV-2 infection, so it is very important to verify their effectiveness and safety. This review summarises the new advances in diabetes therapy and COVID-19 and provides clinical recommendations that are essential for medical doctors and for patients suffering from type 2 diabetes.<\/jats:p>","DOI":"10.3390\/ijms22147605","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T10:52:58Z","timestamp":1626432778000},"page":"7605","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Therapy of Type 2 Diabetes in Patients with SARS-CoV-2 Infection"],"prefix":"10.3390","volume":"22","author":[{"given":"Weronika","family":"Bielka","sequence":"first","affiliation":[{"name":"Department of Physiology, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Przezak","sequence":"additional","affiliation":[{"name":"Department of Physiology, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6557-1208","authenticated-orcid":false,"given":"Andrzej","family":"Pawlik","sequence":"additional","affiliation":[{"name":"Department of Physiology, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S2213-8587(20)30271-0","article-title":"Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: A population-based cohort study","volume":"8","author":"Holman","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"198","DOI":"10.4239\/wjd.v12.i3.198","article-title":"Diabetes and COVID-19: Diseases of racial, social and glucose intolerance","volume":"12","author":"Chowdhury","year":"2021","journal-title":"World J. Diabetes"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41574-020-00435-4","article-title":"COVID-19 and diabetes mellitus: From pathophysiology to clinical management","volume":"17","author":"Lim","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","article-title":"Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target","volume":"46","author":"Zhang","year":"2020","journal-title":"Intensive Care Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"101160","DOI":"10.1016\/j.isci.2020.101160","article-title":"The MERS-CoV Receptor DPP4 as a Candidate Binding Target of the SARS-CoV-2 Spike","volume":"23","author":"Li","year":"2020","journal-title":"iScience"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72,314 Cases from the Chinese Center for Disease Control and Prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"ref_7","first-page":"442","article-title":"Type 2 Diabetes and its Impact on the Immune System","volume":"16","author":"Berbudi","year":"2020","journal-title":"Curr. Diabetes Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.cmet.2020.07.015","article-title":"Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1\u03b1\/Glycolysis-Dependent Axis","volume":"32","author":"Codo","year":"2020","journal-title":"Cell Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/cen.14288","article-title":"COVID-19 and diabetes: Insulin requirements parallel illness severity in critically unwell patients","volume":"93","author":"Wu","year":"2020","journal-title":"Clin. Endocrinol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1172\/JCI114142","article-title":"Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance","volume":"84","author":"Groop","year":"1989","journal-title":"J. Clin. Investig."},{"key":"ref_11","first-page":"e9438","article-title":"A Review of Postmortem Findings in Patients with COVID-19","volume":"12","author":"Eketunde","year":"2020","journal-title":"Cureus"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Guo, W., Li, M., Dong, Y., Zhou, H., Zhang, Z., Tian, C., Qin, R., Wang, H., Shen, Y., and Du, K. (2020). Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab. Res. Rev., e3319.","DOI":"10.1002\/dmrr.3319"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jama.290.3.374","article-title":"Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome","volume":"290","author":"Lew","year":"2003","journal-title":"JAMA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1186\/s13054-020-03255-0","article-title":"Longitudinal changes of inflammatory parameters and their correlation with disease severity and outcomes in patients with COVID-19 from Wuhan, China","volume":"24","author":"Zeng","year":"2020","journal-title":"Crit. Care"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1161\/01.CIR.103.13.1718","article-title":"Inflammation and thrombosis: The clot thickens","volume":"103","author":"Libby","year":"2001","journal-title":"Circulation"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.2147\/DMSO.S244432","article-title":"Integrated Datasets of Proteomic and Metabolomic Biomarkers to Predict Its Impacts on Comorbidities of Type 2 Diabetes Mellitus","volume":"13","author":"Cheema","year":"2020","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1007\/s00125-020-05180-x","article-title":"Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: The CORONADO study","volume":"63","author":"Cariou","year":"2020","journal-title":"Diabetologia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"9526701","DOI":"10.1155\/2021\/9526701","article-title":"The Cytokine Profiles and Immune Response Are Increased in COVID-19 Patients with Type 2 Diabetes Mellitus","volume":"2021","author":"Zheng","year":"2021","journal-title":"J. Diabetes Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/ni.3120","article-title":"NK cells link obesity-induced adipose stress to inflammation and insulin resistance","volume":"16","author":"Wensveen","year":"2015","journal-title":"Nat. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/jdi.13002","article-title":"Relationship between natural killer cell activity and glucose control in patients with type 2 diabetes and prediabetes","volume":"10","author":"Kim","year":"2019","journal-title":"J. Diabetes Investig."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejim.2020.04.037","article-title":"The pivotal link between ACE2 deficiency and SARS-CoV-2 infection","volume":"76","author":"Verdecchia","year":"2020","journal-title":"Eur. J. Intern. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1182\/blood-2012-09-459156","article-title":"Angiotensin 1-7 and Mas decrease thrombosis in Bdkrb2\u2212\/\u2212 mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation","volume":"121","author":"Fang","year":"2013","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1152\/physrev.00023.2016","article-title":"The ACE2\/Angiotensin-(1-7)\/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7)","volume":"98","author":"Santos","year":"2018","journal-title":"Physiol. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/emmm.201000080","article-title":"Angiotensin II revisited: New roles in inflammation, immunology and aging","volume":"2","author":"Benigni","year":"2010","journal-title":"EMBO Mol. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/CIRCRESAHA.120.317015","article-title":"Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2","volume":"126","author":"Gheblawi","year":"2020","journal-title":"Circ. Res."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Wang, L., Liang, J., and Leung, P.S. (2015). The ACE2\/Ang-(1-7)\/Mas Axis Regulates the Development of Pancreatic Endocrine Cells in Mouse Embryos. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0128216"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/jmv.25887","article-title":"Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic","volume":"92","author":"Brufsky","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00592-009-0109-4","article-title":"Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes","volume":"47","author":"Yang","year":"2010","journal-title":"Acta Diabetol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s42255-020-00339-7","article-title":"Can COVID-19 cause diabetes?","volume":"3","author":"Accili","year":"2021","journal-title":"Nat. Metab."},{"key":"ref_30","unstructured":"Liu, W.Z., and Li, H.L. (2020). COVID-19: Attacks the 1-\u03b2 chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism. ChemRxiv."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2174\/1871520619666190626120359","article-title":"Hypoxia-inducible Factor-1\u03b1 Mediates Hyperglycemia-induced Pancreatic Cancer Glycolysis","volume":"19","author":"Cheng","year":"2019","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2020.04.006","article-title":"Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan","volume":"146","author":"Li","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.cell.2019.05.003","article-title":"Lactate Is a Natural Suppressor of RLR Signaling by Targeting MAVS","volume":"178","author":"Zhang","year":"2019","journal-title":"Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/jmcb\/mjaa054","article-title":"COVID-19 and diabetes: The contributions of hyperglycemia","volume":"12","author":"Wang","year":"2021","journal-title":"J. Mol. Cell Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/713609354","article-title":"Dipeptidyl-peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP IV","volume":"40","author":"Lambeir","year":"2003","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","article-title":"The biology of incretin hormones","volume":"3","author":"Drucker","year":"2006","journal-title":"Cell Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/1753-0407.13052","article-title":"COVID-19 and comorbidities: A role for dipeptidyl peptidase 4 (DPP4) in disease severity?","volume":"12","author":"Bassendine","year":"2020","journal-title":"J. Diabetes"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cei.12781","article-title":"Cut to the chase: A review of CD26\/dipeptidyl peptidase-4\u2032s (DPP4) entanglement in the immune system","volume":"185","author":"Klemann","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"ref_39","first-page":"386","article-title":"DPP4 in Diabetes","volume":"6","author":"Wronkowitz","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1128\/JVI.02935-13","article-title":"Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus","volume":"88","author":"Raj","year":"2014","journal-title":"J. Virol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"107503","DOI":"10.1016\/j.pharmthera.2020.107503","article-title":"Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions","volume":"209","author":"Shao","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nature12005","article-title":"Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC","volume":"495","author":"Raj","year":"2013","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/22221751.2020.1739565","article-title":"Emerging WuHan (COVID-19) coronavirus: Glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26","volume":"9","author":"Vankadari","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00005-020-00602-5","article-title":"DPP4 Inhibitors and COVID-19-Holy Grail or Another Dead End?","volume":"69","author":"Grzela","year":"2021","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1365-3083.2010.02488.x","article-title":"Soluble CD26\/dipeptidyl peptidase IV enhances human lymphocyte proliferation in vitro independent of dipeptidyl peptidase enzyme activity and adenosine deaminase binding","volume":"73","author":"Yu","year":"2011","journal-title":"Scand. J. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.virol.2018.03.015","article-title":"Reduction of soluble dipeptidyl peptidase 4 levels in plasma of patients infected with Middle East respiratory syndrome coronavirus","volume":"518","author":"Inn","year":"2018","journal-title":"Virology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1038\/s41366-020-00689-y","article-title":"Circulating levels of soluble Dipeptidylpeptidase-4 are reduced in human subjects hospitalized for severe COVID-19 infections","volume":"44","author":"Schlicht","year":"2020","journal-title":"Int. J. Obes."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3389\/fendo.2019.00389","article-title":"Clinical Use of DPP-4 Inhibitors","volume":"10","author":"Gallwitz","year":"2019","journal-title":"Front. Endocrinol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/1753-0407.13050","article-title":"Do novel drugs for diabetes help in COVID-19? Another brick in the wall?","volume":"12","author":"Grzela","year":"2020","journal-title":"J. Diabetes"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00592-020-01539-z","article-title":"Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19","volume":"57","author":"Solerte","year":"2020","journal-title":"Acta Diabetol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1179551420912972","DOI":"10.1177\/1179551420912972","article-title":"Dipeptidyl Peptidase-4 at the Interface between Inflammation and Metabolism","volume":"13","author":"Trzaskalski","year":"2020","journal-title":"Clin. Med. Insights Endocrinol. Diabetes"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1253\/circj.CJ-12-1168","article-title":"Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes","volume":"77","author":"Matsubara","year":"2013","journal-title":"Circ. J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.metabol.2012.09.004","article-title":"A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients","volume":"62","author":"Sasaki","year":"2013","journal-title":"Metabolism"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Arulmozhiraja, S., Matsuo, N., Ishitsubo, E., Okazaki, S., Shimano, H., and Tokiwa, H. (2016). Comparative Binding Analysis of Dipeptidyl Peptidase IV (DPP-4) with Antidiabetic Drugs\u2014An Ab Initio Fragment Molecular Orbital Study. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0166275"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2478\/acph-2021-0013","article-title":"Sitagliptin: A potential drug for the treatment of COVID-19?","volume":"71","author":"Bardaweel","year":"2021","journal-title":"Acta Pharm."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1038\/s41598-019-43730-5","article-title":"Dipeptidyl peptidase-4 plays a pathogenic role in BSA-induced kidney injury in diabetic mice","volume":"9","author":"Takagaki","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/dmrr.2723","article-title":"DPP-4 inhibitors and risk of infections: A meta-analysis of randomized controlled trials","volume":"32","author":"Yang","year":"2016","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Vora, K.A., Porter, G., Peng, R., Cui, Y., Pryor, K., Eiermann, G., and Zaller, D.M. (2009). Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses. BMC Immunol., 10.","DOI":"10.1186\/1471-2172-10-19"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/cei.12144","article-title":"Effects of short-term sitagliptin treatment on immune parameters in healthy individuals, a randomized placebo-controlled study","volume":"174","author":"Price","year":"2013","journal-title":"Clin. Exp. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.diabres.2016.06.020","article-title":"The effect of dipeptidyl peptidase-IV inhibition on circulating T cell subpopulations in patients with type 2 diabetes mellitus","volume":"118","author":"Sromova","year":"2016","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.2337\/dc20-1521","article-title":"Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study","volume":"43","author":"Solerte","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.2337\/dc20-1340","article-title":"Impact of Comorbidities and Glycemia at Admission and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes With COVID-19: A Case Series From an Academic Hospital in Lombardy, Italy","volume":"43","author":"Mirani","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.2337\/dc20-0660","article-title":"Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication","volume":"43","author":"Chen","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1111\/dom.14097","article-title":"Exposure to dipeptidyl-peptidase-4 inhibitors and COVID-19 among people with type 2 diabetes: A case-control study","volume":"22","author":"Fadini","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.diabet.2020.05.008","article-title":"Prognostic factors in patients with diabetes hospitalized for COVID-19: Findings from the CORONADO study and other recent reports","volume":"46","author":"Scheen","year":"2020","journal-title":"Diabetes Metab."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1093\/ehjcvp\/pvaa098","article-title":"The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: An observational study","volume":"7","author":"Dalan","year":"2021","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2042018821996482","DOI":"10.1177\/2042018821996482","article-title":"Dipeptidyl peptidase-4 inhibitor use and mortality in COVID-19 patients with diabetes mellitus: An updated systematic review and meta-analysis","volume":"12","author":"Pal","year":"2021","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41574-018-0016-2","article-title":"Glucagon-like peptide 1 in health and disease","volume":"14","author":"Andersen","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.2337\/dc12-2469","article-title":"Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes","volume":"36","author":"Ceriello","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3094642","DOI":"10.1155\/2016\/3094642","article-title":"Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control","volume":"2016","author":"Lee","year":"2016","journal-title":"Mediat. Inflamm."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"bnaa011","DOI":"10.1210\/endrev\/bnaa011","article-title":"Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications","volume":"41","author":"Drucker","year":"2020","journal-title":"Endocr. Rev."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Mirabelli, M., Chiefari, E., Puccio, L., Foti, D.P., and Brunetti, A. (2020). Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17103664"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.tem.2018.01.011","article-title":"Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns","volume":"29","author":"Lim","year":"2018","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1677\/JOE-08-0468","article-title":"A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules","volume":"201","author":"Liu","year":"2009","journal-title":"J. Endocrinol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jaci.2018.01.053","article-title":"Glucagon-like peptide 1 receptor signaling attenuates respiratory syncytial virus-induced type 2 responses and immunopathology","volume":"142","author":"Bloodworth","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00395-015-0465-x","article-title":"Gliptin and GLP-1 analog treatment improves survival and vascular inflammation\/dysfunction in animals with lipopolysaccharide-induced endotoxemia","volume":"110","author":"Steven","year":"2015","journal-title":"Basic Res. Cardiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"118645","DOI":"10.1016\/j.lfs.2020.118645","article-title":"GLP-1 mimetics and cognition","volume":"264","author":"Yaribeygi","year":"2021","journal-title":"Life Sci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/jgh.13026","article-title":"Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"31","author":"Carbone","year":"2016","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"108146","DOI":"10.1016\/j.diabres.2020.108146","article-title":"Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?","volume":"163","author":"Pal","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19","volume":"382","author":"Vaduganathan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/path.2987","article-title":"Acute respiratory distress syndrome leads to reduced ratio of ACE\/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist","volume":"225","author":"Lutter","year":"2011","journal-title":"J. Pathol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury","volume":"11","author":"Kuba","year":"2005","journal-title":"Nat. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1007\/s00109-006-0094-9","article-title":"Lessons from SARS: Control of acute lung failure by the SARS receptor ACE2","volume":"84","author":"Kuba","year":"2006","journal-title":"J. Mol. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1210\/en.2014-1685","article-title":"Activation of the GLP-1 Receptor by Liraglutide Increases ACE2 Expression, Reversing Right Ventricle Hypertrophy, and Improving the Production of SP-A and SP-B in the Lungs of Type 1 Diabetes Rats","volume":"156","author":"Moya","year":"2015","journal-title":"Endocrinology"},{"key":"ref_85","first-page":"6920620","article-title":"Liraglutide Enhances the Activity of the ACE-2\/Ang(1-7)\/Mas Receptor Pathway in Lungs of Male Pups from Food-Restricted Mothers and Prevents the Reduction of SP-A","volume":"2018","author":"Vaz","year":"2018","journal-title":"Int. J. Endocrinol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1007\/s13300-020-00898-8","article-title":"ACE2 and SARS-CoV-2 Infection: Might GLP-1 Receptor Agonists Play a Role?","volume":"11","author":"Monda","year":"2020","journal-title":"Diabetes Ther."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","article-title":"Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors","volume":"136","author":"Nauck","year":"2017","journal-title":"Circulation"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/2047487319880040","article-title":"Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases","volume":"26","author":"Prattichizzo","year":"2019","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e3191","DOI":"10.1002\/dmrr.3191","article-title":"The use of GLP-1 receptor agonists in hospitalised patients: An untapped potential","volume":"35","author":"Mustafa","year":"2019","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"R211","DOI":"10.1530\/EJE-19-0566","article-title":"MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?","volume":"181","author":"Nauck","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.dsx.2020.04.019","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic","volume":"14","author":"Cure","year":"2020","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.diabet.2018.09.005","article-title":"Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease","volume":"44","author":"Bonnet","year":"2018","journal-title":"Diabetes Metab."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/dom.13301","article-title":"Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers","volume":"20","author":"Dekkers","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.metabol.2018.02.002","article-title":"Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes","volume":"85","author":"Garvey","year":"2018","journal-title":"Metabolism"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.dsx.2020.04.024","article-title":"Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis","volume":"14","author":"Cure","year":"2020","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2000547","DOI":"10.1183\/13993003.00547-2020","article-title":"Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis","volume":"55","author":"Guan","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2174\/1573399813666170816142351","article-title":"Benefits of SGLT2 Inhibitors Beyond Glycemic Control\u2014A Focus on Metabolic, Cardiovascular and Renal Outcomes","volume":"14","author":"Minze","year":"2018","journal-title":"Curr. Diabetes Rev."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s13300-020-00844-8","article-title":"Lack of Efficacy of SGLT2-i in Severe Pneumonia Related to Novel Coronavirus (nCoV) Infection: No Little Help from Our Friends","volume":"11","author":"Bossi","year":"2020","journal-title":"Diabetes Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/dom.14296","article-title":"Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study","volume":"23","author":"Kosiborod","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrneph.2016.159","article-title":"Acute kidney injury from SGLT2 inhibitors: Potential mechanisms","volume":"12","author":"Hahn","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S2213-8587(20)30152-2","article-title":"Practical recommendations for the management of diabetes in patients with COVID-19","volume":"8","author":"Bornstein","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/dom.14057","article-title":"COVID-19 infection may cause ketosis and ketoacidosis","volume":"22","author":"Li","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/CIRCRESAHA.116.308445","article-title":"Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status","volume":"119","author":"Cameron","year":"2016","journal-title":"Circ. Res."},{"key":"ref_104","first-page":"168","article-title":"The effects of metformin on the fibrinolytic system in diabetic and non-diabetic subjects","volume":"17","author":"Grant","year":"1991","journal-title":"Diabete Metab."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Lu, D.Y., Huang, C.C., Huang, P.H., Chung, C.M., Lin, S.J., Chen, J.W., Chan, W.L., and Leu, H.B. (2014). Metformin use in patients with type 2 diabetes mellitus is associated with reduced risk of deep vein thrombosis: A non-randomized, pair-matched cohort study. BMC Cardiovasc. Disord., 14.","DOI":"10.1186\/1471-2261-14-187"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"36222","DOI":"10.1038\/srep36222","article-title":"Metformin Uniquely Prevents Thrombosis by Inhibiting Platelet Activation and mtDNA Release","volume":"6","author":"Xin","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/apha.12644","article-title":"Metformin is not just an antihyperglycaemic drug but also has protective effects on the vascular endothelium","volume":"219","author":"Triggle","year":"2017","journal-title":"Acta Physiol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"244","DOI":"10.2337\/dc19-0923","article-title":"Reports of Lactic Acidosis Attributed to Metformin, 2015\u20132018","volume":"43","author":"Flory","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"100290","DOI":"10.1016\/j.obmed.2020.100290","article-title":"Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection","volume":"19","author":"Hariyanto","year":"2020","journal-title":"Obes. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1016\/j.dsx.2020.11.006","article-title":"The Effect of Metformin Consumption on Mortality in Hospitalized COVID-19 patients: A systematic review and meta-analysis","volume":"14","author":"Lukito","year":"2020","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4269\/ajtmh.20-0375","article-title":"Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis","volume":"103","author":"Luo","year":"2020","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"119371","DOI":"10.1016\/j.lfs.2021.119371","article-title":"Effects of metformin, insulin on COVID-19 patients with pre-existed type 2 diabetes: A multicentral retrospective study","volume":"275","author":"Cheng","year":"2021","journal-title":"Life Sci."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/cts.12897","article-title":"Risk of Metformin in Patients With Type 2 Diabetes With COVID-19: A Preliminary Retrospective Report","volume":"13","author":"Gao","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"645194","DOI":"10.3389\/fendo.2021.645194","article-title":"The Efficacy and Potential Mechanisms of Metformin in the Treatment of COVID-19 in the Diabetics: A Systematic Review","volume":"12","author":"Zangiabadian","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.cmet.2020.08.013","article-title":"Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes","volume":"32","author":"Cheng","year":"2020","journal-title":"Cell Metab."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/dme.14317","article-title":"Guidelines for the management of diabetes in care homes during the Covid-19 pandemic","volume":"37","author":"Sinclair","year":"2020","journal-title":"Diabet. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.dsx.2020.04.004","article-title":"Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations","volume":"14","author":"Singh","year":"2020","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"108268","DOI":"10.1016\/j.diabres.2020.108268","article-title":"Is metformin ahead in the race as a repurposed host-directed therapy for patients with diabetes and COVID-19?","volume":"165","author":"Singh","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"108183","DOI":"10.1016\/j.diabres.2020.108183","article-title":"Metformin in COVID-19: A possible role beyond diabetes","volume":"164","author":"Sharma","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1080\/10715762.2019.1624742","article-title":"Pioglitazone ameliorates hepatic damage in irradiated rats via regulating anti-inflammatory and antifibrogenic signalling pathways","volume":"53","author":"Radwan","year":"2019","journal-title":"Free Radic. Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1089\/vim.2010.0016","article-title":"PPAR-gamma activation as an anti-inflammatory therapy for respiratory virus infections","volume":"23","author":"Song","year":"2010","journal-title":"Viral Immunol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.dsx.2020.05.007","article-title":"Role of oxidized LDL-induced \u201ctrained macrophages\u201d in the pathogenesis of COVID-19 and benefits of pioglitazone: A hypothesis","volume":"14","author":"Erol","year":"2020","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1111\/dom.14105","article-title":"Influence of diabetes mellitus on the severity and fatality of SARS-CoV-2 (COVID-19) infection","volume":"22","author":"Wu","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.1038\/s41598-019-41854-2","article-title":"Efficacy and Safety of Pioglitazone Monotherapy in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials","volume":"9","author":"Alam","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after Ischemic Stroke or Transient Ischemic Attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Roca-Ho, H., Riera, M., Palau, V., Pascual, J., and Soler, M.J. (2017). Characterization of ACE and ACE2 Expression within Different Organs of the NOD Mouse. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18030563"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.2337\/dc20-0723","article-title":"Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control?","volume":"43","author":"Sardu","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"dgaa360","DOI":"10.1210\/clinem\/dgaa360","article-title":"Diabetic Ketoacidosis in COVID-19: Unique Concerns and Considerations","volume":"105","author":"Palermo","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_130","first-page":"939","article-title":"Diab\u00e8te et infection \u00e0 COVID-19 [Diabetes and COVID-19 infection]","volume":"16","author":"Kosinski","year":"2020","journal-title":"Rev. Med. Suisse"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/1753-0407.13036","article-title":"Care for diabetes with COVID-19: Advice from China","volume":"12","author":"Wang","year":"2020","journal-title":"J. Diabetes"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2021). Standards of Medical Care in Diabetes-2021. Diabetes Care, 44, S15\u2013S33.","DOI":"10.2337\/dc21-S002"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1007\/s00125-020-05209-1","article-title":"Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: A multi-centre retrospective study","volume":"63","author":"Wang","year":"2020","journal-title":"Diabetologia"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"526","DOI":"10.2337\/dc20-2260","article-title":"COVID-19 Severity Is Tripled in the Diabetes Community: A Prospective Analysis of the Pandemic\u2019s Impact in Type 1 and Type 2 Diabetes","volume":"44","author":"Gregory","year":"2021","journal-title":"Diabetes Care"},{"key":"ref_135","first-page":"85","article-title":"Managing Diabetes during the COVID-19 Pandemic","volume":"16","author":"Doupis","year":"2020","journal-title":"Eur. Endocrinol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/14\/7605\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:31:23Z","timestamp":1760164283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/14\/7605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,16]]},"references-count":135,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["ijms22147605"],"URL":"https:\/\/doi.org\/10.3390\/ijms22147605","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2021,7,16]]}}}